NCT00392990 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 25
- units
- Participants
- groups
- description
- Patients are stratified between high risk and low risk disease status. High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated. Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
- id
- BG000
- title
- High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles
- description
- Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses) 4 doses)
- id
- BG001
- title
- Low Risk - Treatment With 3 Cycles of R-CODOX-M
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 21
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Female
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 22
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 22
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 25
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Positive
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 21
- title
- Negative
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Human Immunodeficiency Virus (HIV) Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 8
- title
- Within Normal Range
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 17
- title
- Elevated
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Lactate dehydrogenase (LDH) Level
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 9
- title
- 0
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- 1
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 6
- title
- 2
- description
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) determines the ability of patients being able to tolerate therapies in serious illness. Scale is as follows: 0 = Asymptomatic, normal activity 1. = Symptomatic but completely ambulatory 2. = Symptomatic, less than 50% of time in bed but not bedbound 3. = In bed more than 50% of the time 4. = 100% bedridden 5. = death
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group Performance Status (ECOG PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 8
- title
- Yes
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 17
- title
- No
- description
- Bulky disease is defined as disease in which there is a tumor mass more than 10 cm in its greatest diameter
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Bulky disease
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Stage I
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Stage II
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- Stage III
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 15
- title
- Stage IV
- description
- Classification for Hodgkin Lymphoma ranging from I-IV with IV being worse disease with liver or bone marrow, lungs or cerebrospinal fluid involvement.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ann Arbor Stage
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 25
- units
- Participants
- groups
- description
- Patients are stratified between high risk and low risk disease status. High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated. Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
- id
- BG000
- title
- High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles
- description
- Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses) 4 doses)
- id
- BG001
- title
- Low Risk - Treatment With 3 Cycles of R-CODOX-M
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 21
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Female
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 22
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 22
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 25
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Positive
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 21
- title
- Negative
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Human Immunodeficiency Virus (HIV) Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 8
- title
- Within Normal Range
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 17
- title
- Elevated
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Lactate dehydrogenase (LDH) Level
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 9
- title
- 0
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- 1
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 6
- title
- 2
- description
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) determines the ability of patients being able to tolerate therapies in serious illness. Scale is as follows: 0 = Asymptomatic, normal activity 1. = Symptomatic but completely ambulatory 2. = Symptomatic, less than 50% of time in bed but not bedbound 3. = In bed more than 50% of the time 4. = 100% bedridden 5. = death
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group Performance Status (ECOG PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 8
- title
- Yes
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 17
- title
- No
- description
- Bulky disease is defined as disease in which there is a tumor mass more than 10 cm in its greatest diameter
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Bulky disease
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Stage I
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Stage II
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- Stage III
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 15
- title
- Stage IV
- description
- Classification for Hodgkin Lymphoma ranging from I-IV with IV being worse disease with liver or bone marrow, lungs or cerebrospinal fluid involvement.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ann Arbor Stage
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle